ESMO Breast Cancer 2026 Industry Satellite Symposium
Prognosis vs Prediction: does high-risk mean high response?
ESMO Breast Cancer 2026
Enhancing personalized care in HR+ early breast cancer: How MGA’s help to individualize risk-based systemic treatment decisions
This ESMO Breast Cancer 2026 Industry Satellite Symposium highlights the growing role of multigene assays in tailoring treatment for HR+ early breast cancer. Gain insights into how genomic risk assessment can support more precise, individualized systemic therapy decisions.
Prognosis vs Prediction: does high-risk mean high response?
Understanding prognosis is not the same as predicting treatment benefit. In this session, explore how multigene assays help distinguish between risk and response, supporting more precise decisions on chemotherapy use and helping to avoid both over- and undertreatment in HR+, HER2- early breast cancer.
Incorporating genomic testing when considering adjuvant CDK4/6 inhibitors
Treatment decisions are rarely driven by a single factor. This session explores how multigene assay results can be combined with clinical and patient characteristics to guide chemotherapy use and may help inform CDK4/6 inhibitor decisions, supporting a more nuanced and individualized treatment approach in HR+ early breast cancer.
Where are we with personalized approaches for node-positive patients?
Node-positive disease no longer means a uniform treatment approach. This session explores how integrating genomic risk assessment with dynamic biomarkers can help refine treatment decisions, identify patients who may safely avoid chemotherapy, and support more personalized care in HR+, HER2- early breast cancer.
MDT Live Focus
MDT Live Focus: Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
This MDT Live Focus session explores how genomic testing on core biopsy samples can support earlier, more informed treatment decisions in HR+, HER2- early breast cancer. Discover how integrating these insights into the diagnostic phase may help guide surgical planning and enable more personalized patient pathways.
EBCC 2026
Deciding Together: How Multigene Assays support Shared Decision Making in early breast cancer
How confident are your treatment decisions in early breast cancer? In this satellite symposium, explore how genomic insights can help reduce uncertainty, support personalized discussions, and align treatment choices with what matters most to your patients.
Loading component...
Loading component...
Loading component...
Other webinar and event recordings
Insights & perspectives from a centralized laboratory in genomic testing
Listen Rick Baehner, MD and Helen Bailey, MD share insights of a centralized laboratory & give perspectives how expertise in genomic testing will...
The pathologist's impact on clinical practice & patients' lives
Hear Prof. Giancarlo Pruneri of the University of Milan providing his insights on the importance of analytical work and the critical need to...
The development of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the analytical validation and the key clinical attributes of the Oncotype...
Clinical validation of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the clinical validation of the Oncotype DX® test in TAILORx (N0 population)...
Future of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the Oncotype DX® test in ongoing trials.
Cancer Network Podcast, S1 Ep17
Drs. Alison Laws, Philip Poorvu, and Sara Hurvitz discuss the utility of the Breast Recurrence Score® test for node-positive, HR+, HER2- breast cancer patients.
Get in touch
Have questions about the Oncotype DX test?
